Prospective, randomized, double-blind phase 2B trial of the TLPO and TLPLDC vaccines to prevent recurrence of resected stage III/IV melanoma: a prespecified 36-month analysis

BACKGROUND: The tumor lysate, particle-loaded, dendritic cell (TLPLDC) vaccine is made by ex vivo priming matured autologous dendritic cells (DCs) with yeast cell wall particles (YCWPs) loaded with autologous tumor lysate (TL). The tumor lysate, particle only (TLPO) vaccine uses autologous TL-loaded...

Descripción completa

Detalles Bibliográficos
Autores principales: Carpenter, Elizabeth Lee, Van Decar, Spencer, Adams, Alexandra M, O’Shea, Anne E, McCarthy, Patrick, Chick, Robert Connor, Clifton, Guy Travis, Vreeland, Timothy, Valdera, Franklin A, Tiwari, Ankur, Hale, Diane, Kemp Bohan, Phillip, Hickerson, Annelies, Smolinsky, Todd, Thomas, Katryna, Cindass, Jessica, Hyngstrom, John, Berger, Adam C, Jakub, James, Sussman, Jeffrey J, Shaheen, Montaser F, Yu, Xianzhong, Wagner, Thomas E, Faries, Mark, Peoples, George E
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10401209/
https://www.ncbi.nlm.nih.gov/pubmed/37536936
http://dx.doi.org/10.1136/jitc-2023-006665

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10401209/
https://www.ncbi.nlm.nih.gov/pubmed/37536936
http://dx.doi.org/10.1136/jitc-2023-006665

Ejemplares similares